title: Periconceptional multivitamin use and risk of preterm or small-for-gestational-age births in the Danish National Birth Cohort.
abstract: BACKGROUND
  The intake of periconceptional multivitamins may decrease the risk of preterm births (PTBs) or small-for-gestational-age (SGA) births.
  
  
  OBJECTIVE
  We related the timing and frequency of periconceptional multivitamin use to SGA births and PTBs and its clinical presentations (ie, preterm labor, premature rupture of membranes, and medical induction).
  
  
  METHODS
  Women in the Danish National Birth Cohort (n = 35,897) reported the number of weeks of multivitamin use during a 12-wk periconceptional period. Cox regression was used to estimate the relation between any multivitamin use and PTBs (<37 wk) or SGA births (birth weight adjusted for gestational age >2 SDs below the mean on the basis of fetal growth curves). The timing (preconception and postconception) and frequency of use were also analyzed. Regular users (4-6 wk) and partial users (1-3 wk) in each period were compared with nonusers.
  
  
  RESULTS
  The association between periconceptional multivitamin use and PTBs varied according to prepregnancy overweight status (P-interaction = 0.07). Regular preconception and postconception multivitamin use in women with a prepregnancy BMI (in kg/m(2)) <25 was associated with reduced risks of a PTB (HR: 0.84; 95% CI: 0.73, 0.95) and preterm labor (HR: 0.80; 95% CI: 0.69, 0.94). No similar associations were shown for overweight women. The adjusted risk of an SGA birth was reduced in multivitamin users regardless of their prepregnancy BMI (HR: 0.83; 95% CI: 0.73, 0.95), with the strongest association in regular users in the postconception period.
  
  
  CONCLUSIONS
  Regular periconceptional multivitamin use was associated with reduced risk of SGA births and PTBs in nonoverweight women.
authors.affiliation: Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, PA, USA. catovjm@upmc.edu
authors.forename: Janet M
authors.initials: JM
authors.lastname: Catov
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Bodnar
authors.forename: Jorn
authors.initials: J
authors.lastname: Olsen
authors.forename: Sjurdur
authors.initials: S
authors.lastname: Olsen
authors.forename: Ellen A
authors.initials: EA
authors.lastname: Nohr
mesh_terms: D000328:Adult; D001724:Birth Weight / Q000187:drug effects; D015331:Cohort Studies; D003718:Denmark; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007236:Infant, Small for Gestational Age; D039382:Maternal Nutritional Physiological Phenomena; D050177:Overweight / Q000150:complications*; D011247:Pregnancy; D011248:Pregnancy Complications; D047928:Premature Birth / Q000209:etiology / Q000517:prevention & control*; D016016:Proportional Hazards Models; D012307:Risk Factors; D014815:Vitamins / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D014815:Vitamins